Clinical Usefulness of the Active Fixation Quadripolar Left Ventricular Lead Compared With the Passive Fixation Quadripolar Lead in Cardiac Resynchronization Therapy.

Cardiac resynchronization therapy Left ventricular lead-related complications Quadripolar active fixation lead

Journal

Circulation journal : official journal of the Japanese Circulation Society
ISSN: 1347-4820
Titre abrégé: Circ J
Pays: Japan
ID NLM: 101137683

Informations de publication

Date de publication:
04 Jul 2024
Historique:
medline: 4 7 2024
pubmed: 4 7 2024
entrez: 3 7 2024
Statut: aheadofprint

Résumé

This study compared the stability of the Medtronic Attain Stability Quad (ASQ), a novel quadripolar active fixation left ventricular (LV) lead with a side helix, to that of conventional quadripolar leads with passive fixation (non-ASQ) and evaluated their LV lead performance.Methods and Results: In all, 183 consecutive patients (69 ASQ, 114 non-ASQ) who underwent cardiac resynchronization therapy (CRT) between January 2018 and June 2021 were enrolled. Complications, including elevated pacing capture threshold (PCT) levels, phrenic nerve stimulation (PNS), and LV lead dislodgement, were analyzed during the postimplantation period until the first outpatient visit after discharge. The frequency of LV lead-related complications was significantly lower in the ASQ than non-ASQ group (14% vs. 30%, respectively; P=0.019). Specifically, LV lead dislodgement occurred only in the non-ASQ group, and elevated PCT levels were significantly lower in the ASQ group (7% vs. 23%; P=0.007). Kaplan-Meier analysis confirmed a significantly lower incidence of LV lead-related complications in the ASQ group (log-rank P=0.005). Cox multivariable regression analysis showed a significant reduction in lead-related complications associated with ASQ (hazard ratio 0.44; 95% confidence interval 0.23-0.83; P=0.011). The ASQ group exhibited fewer LV lead-related complications requiring reintervention and setting changes than the non-ASQ group. Thus, the ASQ may be a favorable choice for CRT device implantation.

Sections du résumé

BACKGROUND BACKGROUND
This study compared the stability of the Medtronic Attain Stability Quad (ASQ), a novel quadripolar active fixation left ventricular (LV) lead with a side helix, to that of conventional quadripolar leads with passive fixation (non-ASQ) and evaluated their LV lead performance.Methods and Results: In all, 183 consecutive patients (69 ASQ, 114 non-ASQ) who underwent cardiac resynchronization therapy (CRT) between January 2018 and June 2021 were enrolled. Complications, including elevated pacing capture threshold (PCT) levels, phrenic nerve stimulation (PNS), and LV lead dislodgement, were analyzed during the postimplantation period until the first outpatient visit after discharge. The frequency of LV lead-related complications was significantly lower in the ASQ than non-ASQ group (14% vs. 30%, respectively; P=0.019). Specifically, LV lead dislodgement occurred only in the non-ASQ group, and elevated PCT levels were significantly lower in the ASQ group (7% vs. 23%; P=0.007). Kaplan-Meier analysis confirmed a significantly lower incidence of LV lead-related complications in the ASQ group (log-rank P=0.005). Cox multivariable regression analysis showed a significant reduction in lead-related complications associated with ASQ (hazard ratio 0.44; 95% confidence interval 0.23-0.83; P=0.011).
CONCLUSIONS CONCLUSIONS
The ASQ group exhibited fewer LV lead-related complications requiring reintervention and setting changes than the non-ASQ group. Thus, the ASQ may be a favorable choice for CRT device implantation.

Identifiants

pubmed: 38960680
doi: 10.1253/circj.CJ-24-0084
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Akinori Wakamiya (A)

Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center.

Kohei Ishibashi (K)

Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center.

Satoshi Oka (S)

Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center.

Yuichiro Miyazaki (Y)

Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center.

Nobuhiko Ueda (N)

Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center.

Kenzaburo Nakajima (K)

Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center.

Tsukasa Kamakura (T)

Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center.

Mitsuru Wada (M)

Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center.

Yuko Inoue (Y)

Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center.

Koji Miyamoto (K)

Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center.

Satoshi Nagase (S)

Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center.

Takeshi Aiba (T)

Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center.

Kengo Kusano (K)

Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center.

Classifications MeSH